Wong Stephanie 4

What Happened Stephanie Wong, a director of AN2 Therapeutics (ANTX), received a derivative award of 20,400 shares on February 20, 2026. The Form 4 reports the acquisition price as $0.00 (derivative award/grant). This was a grant of equity (not an open-market purchase or sale) and does not represent an immediate cash transaction.

Key Details

• Transaction date: February 20, 2026; Form 4 filed February 23, 2026. Filing did not indicate tardiness in the provided record.
• Transaction type/code: A — Award/Grant (derivative).
• Shares/amount: 20,400 shares; reported price $0.00 (derivative).
• Vesting: Footnote — the option shares vest on February 20, 2027, subject to continuous service through that date.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No sale/exercise: This filing documents a grant only; no immediate exercise or sale of shares was reported.

Context This is an equity award to a board member that vests after one year of continued service. For retail investors, grants signal company compensation decisions but are not the same as an insider buying shares on the open market — they don’t necessarily reflect immediate personal investment. The filing shows a derivative award with vesting conditions; any future value to the insider depends on vesting and any exercise terms or sale that may be reported later.